Cancer begins when mutations in specific genes override the body’s built-in controls on cell division, allowing rogue cells ...

A recent review identifies interleukin-36 (IL-36) as a transformative driver of vascular inflammation, revealing that serum ...

Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the three months and full ...

Protective Effects of Vitamin D in Necrotizing Enterocolitis of Preterm Infants: From Basic Research to Clinical Translation. Journal of Biosciences and Medicines, 14, 42-56. doi: ...

Verastem, Inc. (NASDAQ:VSTM) Q4 2025 Earnings Call Transcript March 4, 2026 Verastem, Inc. misses on earnings expectations. Reported EPS is $-0.5 EPS, expectations were $-0.49. Operator: Good ...

PepGen Inc. , a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies to treat severe neuromuscular and neurological diseases, today announced regulatory ...

By Hugo Francisco de Souza New research suggests that zinc does far more than support immunity, revealing intricate molecular switches that may influence how the heart responds to inflammatory injury.

Salicornia, which is colloquially known as ‘sea asparagus,’ is rapidly emerging as a transformative solution for future food ...

A secondary stress signaling pathway in the response to optic axon injury is an unexpectedly strong contributor to both neurodegeneration and axon regenerative potential.

The BRAFTOVI combination regimen is the only approved targeted regimen for first-line BRAF-V600E mutant metastatic colorectal cancerPivotal results from the Phase 3 portion with mFOLFOX6 of the ...